Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Status: Active

Description

This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation.

Eligibility Criteria

Inclusion Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • General physical condition compatible with the proposed chemotherapy and surgery
  • Stage T3 or T4a, histologically-confirmed NPNSCC requiring orbital or skull base resection: * Stages T3 and T4a disease will be included regardless of nodal status (N0 or N1-3), provided that surgical therapy would require orbital or skull base resection * The surgical oncologist in each institution will determine the need for resection of the orbit OR base of skull at baseline for patients on both Arms A and B and following neo-adjuvant chemotherapy for patients on Arm B ** Resection of skull base will be deemed necessary according to skull base bone erosion by CT or marrow involvement by MRI is noted; for any disease abutting the skull base ** Resection of orbital contents will be deemed necessary according to skull base society guidelines, based on involvement of periorbital fat documented by MRI imaging
  • Patients must be deemed surgically resectable by the surgical teams at each institution and must have a determination of degree of anticipated structure preservation of orbit and skull base; this needs to be determined prior to randomization
  • Patients may not be receiving investigational agents at time of registration, or at any time while on study and during the 4 weeks preceding enrollment
  • Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel and/or both platinum-based chemotherapy agents are excluded; patient must be able to receive at least one of the two proposed chemotherapy regimens
  • Patients with evidence of distant metastases or leptomeningeal disease (LMD) are excluded
  • Patients must not have received previous irradiation for head and neck tumor, skull base, or brain tumors
  • Patients with uncontrolled inter-current illnesses which in the opinion of the investigator will interfere with the ability to undergo therapy including chemotherapy are excluded
  • Patients with a history of a different malignancy are excluded, unless the disease has not progressed for >= 2 years
  • Absolute neutrophil count (ANC) > 1500/mm^3 =< 2 weeks prior to randomization
  • Hemoglobin (Hgb) > 8.0 g/dL =< 2 weeks prior to randomization
  • Platelet count > 100,000/mm^3 =< 2 weeks prior to randomization
  • Creatinine clearance of > 60 ml/min; creatinine clearance may be measured or calculated; if calculating, creatinine clearance, use the Cockroft-Gault formula =< 2 weeks prior to randomization
  • Total bilirubin within normal limits (must be obtained =< 2 weeks prior to randomization)
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the range allowing for eligibility, must be obtained < 2 weeks prior to randomization
  • Alkaline phosphatase must be within the range allowing for eligibility, must be obtained < 2 weeks prior to randomization
  • Patients with a prior history of squamous cell or basal carcinoma of the skin or in situ cervical cancer must have been curatively treated
  • No current peripheral neuropathy > grade 2 at time of randomization
  • Patients must not have any co-existing condition that would preclude full compliance with the study; no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • Women must not be pregnant or breast-feeding * All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy * A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study
  • Patients must have measurable disease; MRI and/or PET/CT scans need to be performed within 2 weeks prior to registration

Locations & Contacts

Connecticut

New Haven
Smilow Cancer Center / Yale-New Haven Hospital
Status: Active
Contact: Barbara Ann Burtness
Phone: 203-785-5702 Email: canceranswers@yale.edu
Yale University
Status: Active
Contact: Barbara Ann Burtness
Phone: 203-785-5702 Email: canceranswers@yale.edu

Georgia

Atlanta
Emory University Hospital / Winship Cancer Institute
Status: Active
Contact: Nabil F. Saba
Phone: 404-778-1868
Emory University Hospital Midtown
Status: Active
Contact: Nabil F. Saba
Phone: 888-946-7447

Idaho

Post Falls
Kootenai Cancer Center
Status: Active
Contact: Benjamin T. Marchello
Phone: 406-969-6060 Email: mccinfo@mtcancer.org

Illinois

Aurora
Rush - Copley Medical Center
Status: Active
Contact: Zhaohui Jin
Phone: 630-978-6212 Email: Cancer.Research@rushcopley.com
Danville
Carle on Vermilion
Status: Active
Contact: Zhaohui Jin
Phone: 800-446-5532 Email: Research@carle.com
Effingham
Carle Physician Group-Effingham
Status: Active
Contact: Zhaohui Jin
Phone: 800-446-5532 Email: Research@carle.com
Mattoon
Carle Physician Group-Mattoon / Charleston
Status: Active
Contact: Zhaohui Jin
Phone: 800-446-5532 Email: Research@carle.com
Urbana
Carle Cancer Center
Status: Active
Contact: Zhaohui Jin
Phone: 800-446-5532 Email: Research@carle.com

Iowa

Des Moines
Broadlawns Medical Center
Status: Active
Contact: Robert J. Behrens
Phone: 515-282-2200
Iowa Lutheran Hospital
Status: Active
Contact: Robert J. Behrens
Phone: 515-241-8704
Iowa Methodist Medical Center
Status: Active
Contact: Robert J. Behrens
Phone: 515-241-6727
Medical Oncology and Hematology Associates-Des Moines
Status: Active
Contact: Robert J. Behrens
Phone: 515-282-2921
West Des Moines
Methodist West Hospital
Status: Active
Contact: Robert J. Behrens
Phone: 515-343-1000

Montana

Billings
Billings Clinic Cancer Center
Status: Active
Contact: Benjamin T. Marchello
Phone: 800-996-2663 Email: research@billingsclinic.org
Bozeman
Bozeman Deaconess Hospital
Status: Active
Contact: Benjamin T. Marchello
Phone: 406-969-6060 Email: mccinfo@mtcancer.org
Great Falls
Benefis Healthcare- Sletten Cancer Institute
Status: Active
Contact: Benjamin T. Marchello
Phone: 406-969-6060 Email: mccinfo@mtcancer.org
Kalispell
Kalispell Regional Medical Center
Status: Active
Contact: Benjamin T. Marchello
Phone: 406-969-6060 Email: mccinfo@mtcancer.org
Missoula
Community Medical Hospital
Status: Active
Contact: Benjamin T. Marchello
Phone: 406-969-6060 Email: mccinfo@mtcancer.org

New York

Buffalo
Roswell Park Cancer Institute
Status: Active
Contact: Anurag K. Singh
Phone: 800-767-9355 Email: askroswell@roswellpark.org

Oklahoma

Oklahoma City
University of Oklahoma Health Sciences Center
Status: Active
Contact: Mohammad Abdul Razaq
Phone: 405-271-8777 Email: ou-clinical-trials@ouhsc.edu

Pennsylvania

Philadelphia
ECOG-ACRIN Cancer Research Group
Status: Active
Contact: Nabil F. Saba
Phone: 404-778-1868

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. Evaluate the structure preservation rate for patients with locally advanced resectable nasal and paranasal sinus squamous cell carcinoma (NPNSCC) with or without neoadjuvant therapy; all patients will undergo surgical resection and postoperative standard care.

II. Evaluate overall survival (OS) for patients with locally advanced resectable NPNSCC with or without neoadjuvant therapy followed by surgical resection and postoperative standard care.

SECONDARY OBJECTIVES:

I. Evaluate progression-free survival (PFS) for this patient population.

II. Examine the rate of structure preservation for the orbit (freedom from orbital exenteration).

III. Evaluate site reported p16 data and correlate with outcome.

IV. Determine the accuracy of baseline/post-chemotherapy magnetic resonance imaging (MRI) and fludeoxyglucose F-18 positron emission tomography/computed tomography (FDG PET/CT)-based prediction of orbit and skull base preservation.

V. Determine the accuracy of baseline/post-chemotherapy MRI and/or FDG PET/CT-based prediction of 2-year overall survival.

TERTIARY OBJECTIVES:

I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events [both clinical and hematologic] and dose modifications).

II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.

III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.

IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided intensity modulated radiation therapy (IMRT) once daily (QD) for 5 fractions per week for 30 fractions. Patients with positive margins/positive extracapsular spread (ECS) in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin intravenously (IV) over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months if < 2 years from study entry and then every 6 months if 2-5 years from study entry.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
ECOG-ACRIN Cancer Research Group

Principal Investigator
Nabil F. Saba

Trial IDs

Primary ID EA3163
Secondary IDs NCI-2017-01364
Clinicaltrials.gov ID NCT03493425